epigenomics
Sitemap Search Contact FAQs



>> Continue Deutsche Version

The information contained in this website does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale in the United States. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the U.S. have not been established. For further important disclaimers please read here.

PRESEPT Study:

Date: 07.05.2010
Clinical Sites Participating: 32
Subjects enrolled: 7940
Cancers identified: 53

Study successful completed. 


Latest news:

PRESEPT Study Results Sponsored by Epigenomics AG Presented at Digestive Disease Week

Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG: PRESEPT Academic Research Study Meets Its Primary Objective

Latest update:
30-07-2010